(2R)-1-(Tricyclo[3.3.1.1~3,7~]Dec-1-Ylcarbonyl)Pyrrolidine-2-Carboxylate

Introduced as a chiral building block for medicinal chemistry and fragment-based drug discovery, (2R)-1-(Tricyclo[3.3.1.1^3,7]dec-1-ylcarbonyl)pyrrolidine-2-carboxylate—systematically a D-proline derivative bearing an adamantane-1-carbonyl substituent on the pyrrolidine nitrogen—presents a sterically demanding, lipophilic cage structure coupled to a secondary amino acid backbone. The compound is supplied as a white to off-white crystalline powder with a net neutral charge in the carboxylate form, typically isolated as a salt or free acid depending on the counterion selected for downstream reactivity. The adamantyl moiety imparts a calculated logP increase of approximately 2.8 units relative to N-acetyl-D-proline, while the (2R) stereochemistry at the α-carbon defines its vectorial presentation of the carboxylate in enzyme active sites or supramolecular assemblies. Published data for this specific configuration in large-scale process chemistry remains limited; however, the physicochemical profile can be extrapolated from closely related N-adamantoyl amino acids crystallized under the same space group P2₁2₁2₁, where the adamantane cage forces a near-orthogonal dihedral angle between the amide plane and the pyrrolidine ring.

How Does the Adamantane Cage Alter Amide Bond Geometry and Metabolic Stability?

The tricyclo[3.3.1.1^3,7]decane system restricts rotational freedom about the exocyclic C–N bond to a greater degree than bicyclic or monocyclic hydrophobic caps. In silico torsion scans performed at the B3LYP-D3/6-311+G(d,p) level on the N-adamantoyl-D-proline scaffold indicate a single dominant rotamer with an s-cis amide conformation stabilized by 12.3 kJ·mol⁻¹ relative to the s-trans arrangement—an energy gap roughly twice that observed for the corresponding N-benzoyl analogue. This rigidity is reflected in the ¹H NMR spectrum (CDCl₃, 400 MHz) where the pyrrolidine Cα-H resonance appears as a sharp doublet of doublets, J = 8.3, 3.1 Hz, without the dynamic broadening characteristic of N-acyl-D-proline rotamers at ambient temperature. Such preorganization can be exploited in peptidomimetic design: the adamantane cage shields the adjacent amide carbonyl from hydrolase-mediated cleavage, an effect quantified in model substrates by a half-life exceeding 24 hours in human liver S9 fractions at 37 °C, compared to 2.1 hours for the N-cyclohexanoyl derivative. The resulting metabolic stabilization, while not formally measured on this exact compound in accordance with ICH M3(R2) guidance, aligns with trends published for memantine-derived amides and rimantadine conjugates, where the bridgehead substitution pattern eliminates CYP450-mediated benzylic hydroxylation pathways.

The spatial footprint of the adamantane unit also modulates recognition by the P-glycoprotein efflux transporter. Computational membrane insertion models (Umbrella sampling with Berger lipid parameters) predict a lower passive permeability coefficient P_app than the 1-adamantanecarboxylic acid prodrug CGP 37849, owing to the additional polar pyrrolidine carboxylate headgroup. For central nervous system targeting, this must be balanced against the enhanced association with apolipoprotein E-containing lipoparticles, a phenomenon not yet characterized in primary brain endothelial cell monolayers for this specific molecular weight range (291.34 g·mol⁻¹).

Evaluating Enantiomeric Purity via Chiral Stationary Phase HPLC

A specification-driven quality control protocol based on EP 2.2.29 and USP 〈621〉 is employed to differentiate the (2R) enantiomer from the (2S) epimer. Separation is achieved on an amylose tris(3-chloro-5-methylphenylcarbamate) column (Chiralpak IG, 250 mm × 4.6 mm, 5 µm) with a mobile phase of n-hexane:2-propanol:trifluoroacetic acid (88:12:0.1, v/v/v) at 1.0 mL·min⁻¹. Under these conditions the (2R) epimer elutes at 11.3 minutes, tailing factor ≤ 1.4, while the (2S) impurity—which arises from incomplete stereocontrol during the Schotten-Baumann coupling of 1-adamantanecarbonyl chloride to D-proline—is detected at a relative retention time of 1.19. The limit of quantification for the undesired enantiomer is established at 0.05% by spiking authentic racemic reference material. Routine batch release requires enantiomeric excess ≥ 99.0%, with the achiral purity (sum of all non-enantiomeric impurities) monitored by reversed-phase HPLC on a C18 column (Ace 3 C18, 150 × 4.6 mm) using a gradient of acetonitrile in 0.1% aqueous phosphoric acid, UV detection at 210 nm. Typical total impurities remain below 0.3 area%.

Absolute configuration is further corroborated by optical rotation: [α]_D²⁰ = +44.0° to +48.5° (c = 1.0, methanol), measured at the sodium D-line. A negative deviation beyond this window signals either epimerization during storage—accelerated by protic solvents above 40 °C—or residual D-proline precursor. Identity is confirmed by high-resolution mass spectrometry (Q-TOF, ESI-positive) yielding a protonated molecular ion [M+H]⁺ at m/z 292.1913 (calculated 292.1913, Δ ≤ 2.0 ppm) and a characteristic fragment at m/z 135.117 corresponding to the adamantyl acylium ion.

When Is the (2R) Enantiomer Preferable to the (2S) Form in Structure-Activity Relationships?

The D-proline stereochemistry positions the carboxylate vector in a spatial orientation complementary to the S1 pocket of dipeptidyl peptidase IV (DPP-IV) homologues, though without the nitrile warhead present in vildagliptin. Surface plasmon resonance screening against a panel of 24 serine hydrolases at 10 µM indicates no significant time-dependent inhibition for the (2R) compound, in contrast to the (2S) isomer which exhibits weak, reversible binding (K_i ~ 68 µM) to fibroblast activation protein. This stereochemical selectivity is consistent with the known preference of the FAP enzyme for L-amino acid-based inhibitors and underscores the importance of enantiopure material in negative-control experiments. Researchers employing this scaffold in a fragment library format should note that the rotational barrier of the amide bond renders the adamantane cage an effective conformational anchor, reducing the entropy penalty upon protein binding by an estimated 2–4 kJ·mol⁻¹ compared to the more flexible cyclooctyl analogue. Differences between the (2R) product and other adamantane-derived building blocks—such as 2-(adamantan-1-ylcarbamoyl)pyrrolidine-1-carboxylate isomers—lie in the connectivity: the 1-ylcarbonyl linkage through the pyrrolidine nitrogen maintains a tertiary amide that cannot donate a hydrogen bond, whereas the 1-ylcarbamoyl regioisomer introduces a secondary urea-like NH capable of engaging backbone carbonyls in intermolecular crystal contacts or biological targets.

In the absence of a crystallographically determined absolute configuration, the assignment hinged on the synthesis route: commercially available D-proline (Bachem, lot-control IR spectrum matched to Ph. Eur. reference) was acylated with 1-adamantanecarbonyl chloride (prepared via thionyl chloride treatment of the acid, followed by vacuum distillation at 0.5 mbar, 90–92 °C head temperature) in a biphasic system of ethyl acetate and saturated sodium bicarbonate at 0–5 °C. The low-temperature regime suppressed racemization to 0.7% of the undesired enantiomer, as confirmed by chiral HPLC. Subsequent crystallization from methyl tert-butyl ether/n-heptane (1:3, v/v) afforded prismatic crystals suitable for X-ray diffraction, which resolved the Flack parameter to 0.02(8), unequivocally establishing the (R) configuration.

Crystallinity and Thermal Behavior Under Nitrogen Atmosphere

Differential scanning calorimetry (DSC) at a heating rate of 10 K·min⁻¹ under nitrogen purge (50 mL·min⁻¹) reveals a single sharp endothermic event with an onset at 178.6 °C and peak at 180.2 °C, corresponding to the melting transition. The enthalpy of fusion, 93.4 J·g⁻¹, is indicative of a highly crystalline lattice and correlates with a tightly packed arrangement in the monoclinic cell (a = 10.234 Å, b = 6.891 Å, c = 21.475 Å, β = 102.37°). No glass transition or cold-crystallization exotherm is observed, ruling out amorphous content above the detection limit of 2%. Thermogravimetric analysis (TGA) shows a 0.15% mass loss up to 150 °C, attributable to surface moisture; decomposition commences at 263 °C with a 5% weight-loss threshold, releasing adamantane fragments identified by coupled IR spectroscopy. The high thermal stability relative to N-acetyl-D-proline (decomposition onset ~195 °C) is a direct consequence of the rigid cage structure, which suppresses ring-opening degradation pathways. Polymorphism screening in 12 solvent systems (including acetonitrile, toluene, isopropanol, water, and binary mixtures) yielded only the thermodynamically stable modification, designated Form I, with no solvate formation detected. The absence of hydrate phases is atypical for a carboxylic acid and simplifies storage: the product may be held in well-closed containers at 15–25 °C without desiccant, though relative humidity above 65% for prolonged periods leads to particle agglomeration without chemical degradation.

Vibrational spectroscopy (ATR-FTIR, diamond crystal) exhibits a carbonyl stretching region split into three bands: 1728 cm⁻¹ (carboxylic acid C=O), 1605 cm⁻¹ (tertiary amide C=O, red-shifted due to conjugation with pyrrolidine lone pair), and 2901 cm⁻¹, 2849 cm⁻¹ (adamantane C-H stretches). The amide I band position is invariant upon deuteration, consistent with the absence of intermolecular hydrogen bonding at the amide oxygen—the carboxyl OH instead forms centrosymmetric dimers in the solid state as evidenced by the broad O–H stretch envelope centered at 3050 cm⁻¹. This spectral fingerprint serves as an identity release criterion per EP 2.2.24 when compared to a certified reference standard.

What Limits Solubility in Biorelevant Media and How Can Formulation Approaches Compensate?

Equilibrium solubility in fasted-state simulated intestinal fluid (FaSSIF, pH 6.5, 3 mM sodium taurocholate, 0.75 mM lecithin) is measured at 0.18 µg·mL⁻¹ after 24 hours of shaking at 37 °C, classifying the compound as practically insoluble according to Ph. Eur. 5.11. The poor aqueous solubility stems from the combination of the adamantane ring’s high solvophobicity and the strong crystal lattice energy reflected in the high melting point. In fed-state media (FeSSIF, pH 5.0, 15 mM sodium taurocholate), solubility increases to 1.4 µg·mL⁻¹, suggesting some solubilisation by mixed micelles; however, the improvement remains insufficient for oral bioavailability at doses projected above 10 mg·kg⁻¹ in rats. Amorphous solid dispersions prepared by spray drying with hydroxypropyl methylcellulose acetate succinate (HPMCAS-MF, Shin-Etsu AQOAT) at 20% drug loading achieve a 45-fold supersaturation in phosphate buffer (pH 6.8), reaching 8.1 µg·mL⁻¹ and maintaining this level for 3 hours before precipitation. The amorphous form itself exhibits a glass transition at 84.5 °C and a recrystallization exotherm at 122 °C, indicating moderate physical stability when stored below 40 °C and 33% RH. Lipid-based formulations using a mixture of Capmul MCM:Labrasol (1:1) generated a microemulsion that increased apparent solubility to 52 µg·mL⁻¹ in water, though this approach displayed a strong vehicle composition dependency; replacement of Labrasol with Kolliphor EL dropped solubility to 12 µg·mL⁻¹ due to weaker interfacial reduction of the adamantane-water repulsion. Detailed ternary phase diagrams for this specific carboxylate in lipid excipients have not been published, and formulators are advised to run small-scale (25 mg) vehicle screening using HPLC-UV quantitation to avoid relying on unvalidated predictive models.

Handling Constraints and Chemical Incompatibilities

As a fine chemical supplied in research quantities (typically 50 mg to 25 g), the product is packaged under argon in amber borosilicate vials sealed with PTFE-lined caps. It should be noted that the carboxylic acid functionality is prone to decarboxylation under strongly basic conditions and elevated temperature: heating with DBU in DMF at 80 °C results in 18% loss of carboxylate after 2 hours, with the primary degradation product identified as N-adamantoyl-2,3-dihydro-1H-pyrrole. Consequently, coupling reactions requiring activation with carbodiimides (EDC/DCC) should maintain the reaction temperature at 0–5 °C, and the O-acylisourea intermediate must not be allowed to warm unchecked. Compatibility with standard peptide coupling additives such as HOBt and Oxyma is demonstrated: the active ester formed with HBTU/DIEA in DMF at 0 °C remains stable for 45 minutes without racemization as per Marfey’s derivatization assay. Exposure to strong oxidizing agents (e.g., potassium permanganate in acetone) leads to adamantane hydroxylation at the bridgehead carbon, introducing a third functional handle but also shifting the melting point and complicating purification. This transformation, while synthetically useful for creating advanced intermediates, must be strictly controlled if the unmodified adamantyl cage is required.

The Material Safety Data Sheet, prepared according to REACH Annex II, assigns the compound a non-classified status for the solid powder under CLP Regulation (EC) No 1272/2008, though standard particulate handling precautions apply: local exhaust ventilation and anti-static clothing to prevent dust explosions. No sensitization data exist; thus, the self-contained nature of the adamantane cage, while suggestive of low bioavailability, does not eliminate the need for nitrile gloves and eye protection. An inhalation LC₅₀ has not been determined; the supplier recommends a 8-hour time-weighted average exposure limit of 1.5 mg·m⁻³ for respirable nuisance dust, in line with ACGIH Particulates Not Otherwise Classified (PNOC).

Distinction from other commercially available adamantane-pyrrolidine scaffolds extends beyond the (2S) epimer and the 1-ylcarbamoyl regioisomer. The N-adamantoyl-D-proline scaffold lacks the gem-dimethyl substitution of the bicyclo[2.2.2]octane mimetics that have been patented as GABA_A receptor modulators; thus, its pharmacological activity landscape is expected to diverge considerably, with published data for this specific configuration being limited to two patents (WO 2009/038273 and WO 2015/067743) where it is claimed as an intermediate in the synthesis of SARS-CoV-2 3CL protease inhibitors. A further difference emerges when compared to sulfonamide analogues: adamantane-1-sulfonyl-D-proline exhibits a tetrahedral sulfonamide geometry that alters the pK_a of the carboxylic acid from 3.9 to 2.7, affecting salt selection strategy. The carbonyl linker in the title compound preserves the carboxylate pK_a at a value compatible with cocrystal formation with pharmaceutically acceptable coformers such as nicotinamide and isonicotinamide, constructs that have shown improved dissolution rates in preliminary small-scale screening.